Carbonic Anhydrase IX Expression in Clear Cell Renal Cell Carcinomas Negatively Correlates With the Proportion of the Granular Cell Component

Abstract

9. Bleumer I, Knuth A, Oosterwijk E, et al: A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br J Cancer 90:985-990, 2004 10. Bleumer I, Oosterwijk E, Oosterwijk-Wakka JC, et al: A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma. J Urol 175:57-62, 2006 11. Steffens MG, Boerman OC, de Mulder PH, et al: Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131 I-labeled chimeric monoclonal antibody G250. Clin Cancer Res 5:3268s-3274s, 1999 (suppl) 12. Brouwers AH, Mulders PF, de Mulder PH, et al: Lack of efficacy of two consecutive treatments of radioimmunotherapy with 131 I-cG250 in patients with metastasized clear cell renal cell carcinoma. J Clin Oncol 23:6540-6548, 2005 13. Brouwers AH, Dorr U, Lang O, et al: 131 I-cG250 monoclonal antibody immunoscintigraphy versus [ 18 F]FDG-PET imaging in patients with metastatic renal cell carcinoma: A comparative study. Nucl Med Commun 23:229-236, 2002 14. Brouwers AH, Buijs WCAM, Oosterwijk E, et al: Targeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody G250 labeled with

Cluster analysis of immunohistochemical profiles delineates CK7, vimentin, S100A1 and C‐kit (CD117) as an optimal panel in the differential diagnosis of renal oncocytoma from its mimics

“…Interestingly, Skapa et al. 27 noted recently that the amount and intensity of reactivity of CAIX in CRCC was related to the proportion of cells with granular cytoplasm, which may explain the lower percentage of CRCC that expressed CAIX in our study. In addition, the reactivity of CAIX in ChRCC was primarily weak in nature.…”

A Study of Angiogenesis Markers in Patients with Renal Cell Carcinoma Undergoing Therapy with Sunitinib

“…Although not statistically significant the data presented here highlight the need for future studies to be conducted on the angiogenesis pathway and to identify new targets for providing better information for treatment selection and prognostic modelling. The results from our data follow the literature and show CA9 and VEGF (19,20) as possible targets for further work.…”

“…It is also important to note that several studies when conducting IHC staining on prepared slides (in an assay similar to those described in our methods) used a semiquantitative scoring system of absent/weak/strong. Maybe the further elucidation of a five tiered scoring system has sub-divided the relatively small sample size and proved to be a limitation to the data analysis and that of a more simple approach (one reflected in Leibovich et al and Skapa et al) would yield more interesting results (12,20).…”

“…ANTICANCER RESEARCH 37: 253-260 (2017) The current literature shows very little progress with work being carried out on angiogenesis markers as predictive factors for RCC, although some show VEGF (19) (and its associated receptor) and CA9 (20) as important factors within the process of angiogenesis (7,9). Although not statistically significant the data presented here highlight the need for future studies to be conducted on the angiogenesis pathway and to identify new targets for providing better information for treatment selection and prognostic modelling.…”

High-dose Interleukin-2 Can Produce a High Rate of Response and Durable Remissions in Appropriately Selected Patients With Metastatic Renal Cancer

“…Moreover, the independence of various factors must be assessed as there may be links between several predictive factors-for example, CAIX expression is inversely correlated with numbers of granular cells. 23 Such issues along with validation of other markers are also being assessed in the "SELECT" study 24 and initial results were reported at ASCO 2010. 25 It is interesting to note that these results 25 do not confirm to the selection criteria proposed by Upton et al 14 or the value of CAIX to select patients for HD IL2.…”